SCHEMBL4286261

SCHEMBL4286261

Cc1nc(NC(=O)c2ccc(N)cc2)sc1C

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 14/20 0.73
NPC1 O15118 14/20 0.73
PKM P14618 2/20 0.73
SMN1; SMN2 Q16637 9/20 0.61
MAPT P10636 6/20 0.61
KMT2A Q03164 7/20 0.58
MEN1 O00255 6/20 0.58
KDM4E B2RXH2 3/20 0.58
ALDH1A1 P00352 4/20 0.56
RXFP1 Q9HBX9 3/20 0.56
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA4 P22748 1/20 0.55
CA7 P43166 1/20 0.55
ATM Q13315 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
NPSR1 Q6W5P4 2/20 0.53
SCD O00767 1/20 0.53
LMNA P02545 2/20 0.52
RECQL P46063 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2754020 0.88 NPC1 (0.77) RAB9ANPC1PKMSMN1; SMN2MAPT
SCHEMBL31665475 0.84 NPC1 (1.00) RAB9ANPC1PKMSMN1; SMN2MAPT
SCHEMBL1969659 0.84 RAB9A (0.64) RAB9ANPC1PKMSMN1; SMN2MAPT
SCHEMBL16607194 0.82 RAB9A (0.69) RAB9ANPC1PKMSMN1; SMN2MAPT
SCHEMBL25143604 0.80 RAB9A (0.58) RAB9ANPC1PKMSMN1; SMN2MAPT
SCHEMBL31665569 0.80 RAB9A (0.58) RAB9ANPC1PKMSMN1; SMN2MAPT
SCHEMBL1966157 0.77 RAB9A (0.56) RAB9ANPC1PKMSMN1; SMN2MAPT
SCHEMBL2175908 0.77 RAB9A (0.77) RAB9ANPC1SMN1; SMN2MAPTKMT2A
SCHEMBL8559786 0.77 RAB9A (0.74) RAB9ANPC1PKMSMN1; SMN2MAPT
SCHEMBL25142527 0.77 RAB9A (0.72) RAB9ANPC1PKMSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
CN-1870996-A N-thiazol-2-yl-benzamide derivatives LUNDBECK & CO AS H (DK) 2006-11-29 CN disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 RAB9A 2380/4885NPC1 1022/4885PKM 1554/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 RAB9A 2380/4885NPC1 1022/4885PKM 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.